Stuck on high alert: Altered immune responses during Long COVID

From the Newell lab, Vaccine and Infectious Disease Division

Long COVID (LC) is a chronic disease that is driven by COVID-19 infection, with symptoms lasting at least three months after initial SARS-CoV-2 infection. Symptoms can persist for years, yet what drives the disease remains unknown. Researchers in the Newell lab in the Vaccine and Infectious Disease Division collaborated with the Roan lab at the Gladstone Institute in a new study to identify how dysregulated immune responses could be contributing to LC symptoms.

During viral infection, sentinel immune T cells survey other cells for signs of infection. When a cell is infected, it will display a chopped up viral protein (antigen) on a surface receptor that T cells recognize. This recognition triggers an antiviral response, where these cells will begin to kill virally infected cells and recruit other immune cells to the site of infection. It also stimulates T cells to differentiate into subsets that fall along a spectrum of activity. At one end are stem-like T cells which are flexible, self-renewing, and long-lived. At the other are terminally differentiated T cells, which are shorter-lived but highly effective killers. During chronic infection, continual antigen exposure can also cause T cells to become exhausted, gradually losing antiviral activity and upregulating inhibitory receptors that dampen stimulation.

To understand how dysregulation of this T cell response contributes to LC, researchers utilized a modified cell-sorting method known as CyTOF (cytometry by time-of-flight) or mass cytometry. This method detects many T cell surface markers at once, allowing researchers to accurately identify both which viruses T cells recognize and their functional state. The researchers applied their CyTOF panel to blood samples from donors who experienced severe active COVID infection, and to samples from the same patients four months after initial infection. Half of these individuals had fully recovered, while the other half had ongoing symptoms that met the criteria for LC.

The results showed that individuals who recovered from their SARS-CoV-2 infection had more stem-like T cells, whereas individuals with LC were deficient in them, indicating that T cell responses are altered in LC. Earlier work suggested that reactivation of other persistent viruses, Epstein-Barr virus (EBV) and cytomegalovirus (CMV), during COVID-19 infection might contribute to LC. The authors therefore examined T cells specific for SARS-CoV-2, EBV, and CMV in recovered and LC individuals. In those with LC, T cells specific for all three viruses showed markers of terminal differentiation, cytolytic (killing) activity, and exhaustion. Cells that are recognizing these viruses are acting like an overprotective parent, doing all the things they would normally do to help you but too much of the time. This data suggests that the dysregulated T cell response in LC may be linked to other persistent viral infections as well.

Graphical abstract: COVID-19 leads to either long COVID or recovery, with CD8+ T cell markers (TIGIT, PD1, CD39, CD38, CD57, Granzyme B, CD29) shown on a cell specific for EBV, SARS-CoV-2, and CMV.
T cells from individuals with Long COVID present markers associated with exhaustion and cytolytic activity. Image from original publication

When T cells kill infected cells, they can release cytotoxic granules that contain proteins called perforins and granzymes. These proteins penetrate the target cell’s membrane and deliver molecules that trigger cell death. The authors found that Granzyme B, a marker for this cytolytic activity, was highly expressed on virus-specific cells during early SARS-CoV-2 infection. In recovered individuals these cytolytic markers declined over time, but in individuals with LC they did not. Notably, this cytolytic signature was stronger in women with LC, which is intriguing given that women are more prone to developing LC than men.

There are currently no treatments for Long COVID symptoms, making it critical to understand how SARS-CoV-2 dysregulates the immune response. This work begins to untangle that mystery, suggesting that the strong, cytolytic T cell response mounted early in infection may persist in people who develop LC. Further studies into the functional consequences of these persistent killer T cells will help uncover the cause of LC and guide the development of effective treatments.


The spotlighted research was funded by the National Institutes of Health.

Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium Member Dr. Evan Newell (Fred Hutch) contributed to this research.

Ma T, Ryu H, Yin K, Dalhuisen T, Robbins D, Bailey TT, Thomas SA, Fehrman EA, Kelly JD, Martin JN, Lynch KL, Lee SA, Deeks SG, Henrich TJ, Peluso MJ, Newell EW, Roan NR. 2026. Persistent cytolytic CD8+ T cells recognize SARS-CoV-2 and herpesvirus epitopes in long COVID. Cell Reports Medicine. DOI: 10.1016/j.xcrm.2026.102946